MULTIPLEX ANALYSIS OF PERIPHERAL BIOMARKERS IN SCHIZOPHRENIC PATIENTS WITH LONG-TERM ANTIPSYCHOTIC THERAPY

QR Code

MULTIPLEX ANALYSIS OF PERIPHERAL BIOMARKERS IN SCHIZOPHRENIC PATIENTS WITH LONG-TERM ANTIPSYCHOTIC THERAPY

Complex clinical and biological study of 115 schizophrenic patients with long-term antipsychotic treatment was carried out. Concentrations of brain-derived neurotrophic factor (BDNF) and prolactin levels in blood serum in schizophrenic patients and healthy subjects were determined to multiplex analy...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. S. Boiko, I. S. Losenkov, E. G. Dmitrieva
Format:	Article
Language:	Russian
Published:	LLC Center of Pharmaceutical Analytics (LLC «CPHA») 2019-01-01
Series:	Разработка и регистрация лекарственных средств
Subjects:	brain-derived neurotrophic factor prolactin schizophrenia multiplex analysis antipsychotic therapy
Online Access:	https://www.pharmjournal.ru/jour/article/view/177
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Is there constitutional and morphological predisposition to akathisia in schizophrenic patients receiving antipsychotic therapy?
by: A. A. Goncharova, et al.
Published: (2020-01-01)

Methods of correction of hyperprolactinemia induced by antipsychotics: current state of the problem and development prospects
by: G. E. Mazo, et al.
Published: (2024-06-01)

Pattern of Antipsychotics in Schizophrenia Outpatients at Lampung Province Mental Hospital
by: Isnenia Isnenia
Published: (2022-03-01)

The antipsychotics functional index (AFI) in schizophrenia
by: Gabriel-Cristian Marinescu, et al.
Published: (2025-07-01)

Sexual differences in the clinical features of antipsychotic-induced hyperprolactinemia in patients with schizophrenia
by: E. G. Kornetova, et al.
Published: (2019-10-01)

CLINICAL AND SOCIAL RISK FACTORS OF TARDIVE DYSKINESIA IN PATIENTS WITH SCHIZOPHRENIA DURING ANTIPSYCHOTIC TREATMENT
by: Ye. G. Kornetova, et al.
Published: (2015-02-01)

Correction: The antipsychotics functional index (AFI) in schizophrenia
by: Gabriel-Cristian Marinescu, et al.
Published: (2025-07-01)

Frequency of occurrence of type 2 diabetes and metabolic disturbances in patients with schizophrenic range disorders with prolonged anti-relapse antipsychotic therapy (based on screening results)
by: L. N. Gorobets, et al.
Published: (2019-07-01)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
by: Montemagni C, et al.
Published: (2016-04-01)

Dopamine receptor DRD1 expression (mRNA, protein level) in peripheral blood lymphocytes and prognosis of antipsychotic therapy
by: A. M. Zabotina, et al.
Published: (2022-11-01)

Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia
by: I. A. Vilyum, et al.
Published: (2018-08-01)

Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia
by: I. A. Vilyum, et al.
Published: (2018-05-01)

Influence of Polymorphisms in Gene SATB2 on Antipsychotics Response in Chinese Han Population
by: Du X, et al.
Published: (2025-07-01)

Brain-derived neurotrophic factor modulates immune reaction in mice with peripheral nerve xenotransplantation
by: Yu X, et al.
Published: (2016-03-01)

Guideline for the use of therapeutic drug monitoring of antipsychotics to individualize the selection of therapy in the treatment of exacerbation of schizophrenia
by: S. S. Potanin, et al.
Published: (2023-12-01)

Neurotrophic Factors in Multiple Sclerosis: a Review of the Mechanism
by: Samaneh Azizpour, et al.
Published: (2025-01-01)

Comparative analysis of EEG in patients with schizophrenia receiving various atypical antipsychotics
by: S. A. Galkin, et al.
Published: (2024-04-01)

CLINICODIAGNOSTIC SIGNIFICANCE OF CILIARY AND BRAIN-DERIVED NEUROTROPHIC FACTORS IN CHILDREN WITH DIABETIC PERIPHERAL NEUROPATHY
by: A. A. Afonin, et al.
Published: (2013-12-01)

Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics
by: de Bartolomeis A, et al.
Published: (2016-01-01)

DOPAMINE RECEPTOR D2 (DRD2) IN PERIPHERAL BLOOD LYMPHOCYTES AS BIOMARKER OF RESPONSE TO ANTIPSYCHOTIC MEDICATION
by: M. N. Grunina, et al.
Published: (2020-05-01)

The Metabolic Indices of Persons with First-Episode Schizophrenia on Antipsychotic Medications: A 12-Week Follow-up Study
by: Tobechukwu C. Iyidobi, et al.
Published: (2025-07-01)

Peculiarities of personalized selection of antipsychotic drugs for schizophrenia treatment
by: O.O. Khaustova, et al.
Published: (2024-04-01)

Screening benzimidazole derivatives for atypical antipsychotic activity
by: K. Yu. Kalitin, et al.
Published: (2025-08-01)

CLINICAL AND DIAGNOSTIC VALUE OF PEROXYNITRITE AND BRAIN-DERIVED NEUROTROPHIC FACTOR IN INFANTS WITH PERINATAL HYPOXIC LESIONS OF THE CNS
by: A. A. Afonin, et al.
Published: (2013-12-01)

Influence of clinical and therapeutic indicators on the severity of neurocognitive deficits in patients with schizophrenia
by: E. G. Kornetova, et al.
Published: (2020-10-01)

Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review
by: Zhang L, et al.
Published: (2016-01-01)

Dynamics of mental state and prolactin levels in patients with chronic schizophrenia during aripiprazole therapy
by: L. N. Gorobets, et al.
Published: (2023-10-01)

Tunable Intranasal Polymersome Nanocarriers Triggered Olanzapine Brain Delivery and Improved In Vivo Antipsychotic Activity
by: Ahmed A. Katamesh, et al.
Published: (2025-06-01)

Brain-derived neurotrophic factor in the pathogenesis of comorbid coronary artery disease and depression: a review
by: O. Yu. Kytikova, et al.
Published: (2024-12-01)

Modern approaches to the therapy of schizophrenia with atypical neuroleptics (based on clinical observations)
by: D. D. Samoylov, et al.
Published: (2024-12-01)

The influence of family history of schizophrenic spectrum disorders on the clinical presentation of schizophrenia
by: V. R. Gashkarimov, et al.
Published: (2024-09-01)

Pharmacogenetics of antipsychotic-induced metabolic disturbances: state-of-the-art
by: R. F. Nasyrova, et al.
Published: (2018-07-01)

Pharmacogenetics biomarkers of antipsychotics’ safety in adolescents with acute psychotic episode
by: D. V. Ivashchenko, et al.
Published: (2019-12-01)

Acute partial sleep restriction attenuates working memory performance and does not affect BDNF in young adults
by: Cherubini Joshua M., et al.
Published: (2025-06-01)

Antipsychotic-Induced Parkinsonism: A Risk Assessment Scale and Personalised Diagnosis Algorithm
by: N. A. Shnayder, et al.
Published: (2025-04-01)

Pharmacotherapy of Psychotic Disorders in Türkiye: Insights From a National Prescription Database
by: Sena Türkeş, et al.
Published: (2025-07-01)

Intravenous administration of adipose tissue-derived stem cells enhances nerve healing and promotes BDNF expression via the TrkB signaling in a rat stroke model
by: Li X, et al.
Published: (2016-06-01)

APPLICATION OF ANTIPSYCHOTICS OF LONG-TERM ACTION IN SCHIZOPHRENIA
by: Zh. B. Bibekova, et al.
Published: (2020-03-01)

The Impact of Physical Activity on Metabolic Health and Cognitive Function in Postmenopausal Women: A Cross-Sectional Study
by: Kinga Mruczyk, et al.
Published: (2025-06-01)

Enhancing Neuroplasticity in the Chronic Phase After Stroke: Effects of a Soft Robotic Exosuit on Training Intensity and Brain-Derived Neurotrophic Factor
by: Anna V. Roto Cataldo, et al.
Published: (2023-01-01)